Vicore Pharma Holding
7,43
SEK
-2,11 %
Mindre end 1K følgere
VICO
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Ownership
Investor consensus
-2,11%
+0,41%
-13,7%
-12,07%
-11,44%
-55,55%
-67,44%
-42,58%
+47,13%
Vicore Pharma operates in the pharmaceutical industry and focuses on the development of innovative treatments for pulmonary and cardiovascular diseases. The company researches new therapies that can improve patient outcomes and quality of life. The business is global with a primary presence in Europe and North America. Vicore Pharma was founded in 2000 and is headquartered in Gothenburg, Sweden.
Læs mereMarkedsværdi
1,74 mia. SEK
Aktieomsætning
2,53 mio. SEK
Omsætning
109,35 mio.
EBIT %
-177,59 %
P/E
-
Udbytteafkast, %
-
Finanskalender
6.5
2025
Generalforsamling '25
6.5
2025
Delårsrapport Q1'25
22.8
2025
Delårsrapport Q2'25
Alle
Selskabspræsentationer
Selskabsmeddelelser
ViserAlle indholdstyper
Vicore to Participate in the Van Lanschot Kempen Life Sciences Conference
Notice of Annual General Meeting of Vicore Pharma Holding AB (publ)
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Vicore publishes the Annual Report for 2024
Year-end report 2024
Vicore to Present at Upcoming Investor Conferences
Vicore to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference
The FDA Grants Vicore’s Buloxibutid Fast Track Designation for Idiopathic Pulmonary Fibrosis
Vicore to Present at Upcoming Investor Conferences
Interim report July-September 2024
Vicore announces the Nomination Committee for the 2025 Annual General Meeting
Increase in number of shares and votes in Vicore Pharma
Vicore Pharma has successfully carried out a directed share issue of approximately SEK 100 million
Vicore Pharma raises approximately SEK 782 million through an oversubscribed rights issue
Vicore Pharma publishes preliminary outcome in the rights issue
Vicore Announces Investment from Sanofi
Vicore Publishes Prospectus Relating to the Rights Issue
Vicore Announces Additional Subscription Undertaking from HealthCap
